Recent strategies to achieve high production yield of recombinant protein: A review

Abstract

Recombinant proteins have long been used in the pharmaceutical, chemical, and agricultural industries. These proteins can be produced in hosts such as mammalian cells, bacteria, insect cells, yeast, and plants. However, the demand for recombinant proteins, especially for the prevention, diagnosis, and treatment of diseases, is increasing. Meeting this growing demand on a large scale remains a challenge for many industries. Developing new tools to increase the yield and quality of these proteins is therefore a necessity. Many strategies to optimize protein production in various expression systems have emerged in recent years. This review summarizes the different characteristics of expression systems, as well as the current strategies used to improve the yield of recombinant proteins.

Keywords

Recombinant protein expression system production strategies

1 Introduction

As modified forms of protein that can be biosynthesized in huge quantities, recombinant proteins are beneficial to the chemical, agricultural, and biopharmaceutical industries [1]. They have already been produced employing several expression systems using mammalian cells, insect cells, yeast, bacteria, plant, and animals as hosts. However, several parameters need to be taken into account for production on a large scale of these proteins. These factors include the recombinant enzyme’s mass, purity, or solubility; the number of disulfide linkages; the required post-translational modifications (PTMs); the location where the expressed enzyme will be used; the cost and ease of use of the protein expression system; and, finally, regulatory issues in the case of pharmaceutical production [2]. Heterologous pharmaceutical proteins have been produced in expression hosts such as Escherichia coli, Streptomyces [3, 4], Pichia pastoris, Saccharomyces cerevisiae [5, 6], and HEK293T cells [7]. Prokaryotic expression systems are very appealing for the expression of recombinant DNA (rDNA). Because of its rapid growth, continuous fermentation capacity, low cost, well-understood metabolism and genetics, and high production yields, Escherichia coli is by far the most widely used host cell for protein expression [3 , 9]. Moreover, the absence of PTMs in the latter makes the yeast Pichia Pastoris, an excellent choice for producing proteins ranging from simple to complex [11]. However, studies are still needed to provide strategies for optimizing the production efficiency of these proteins, given the ever-increasing demand [11, 12]. Recently developed bioengineering and in silico approaches provided an undeniable advantage in terms of yield, cost, and production time, as well as final product quality. The goal of this review is to describe the various expression systems used to biosynthesize recombinant proteins, as well as their benefits and drawbacks, with a focus on current strategies used for high protein production.

2 Literature review

2.1 Strategies for overexpression of protein in prokaryotic expression hosts

2.1.1 Escherichia coli

For over forty years, the E. Coli expression system has been used to produce very huge quantities of recombinant proteins due to its simplicity, speed, easy genetic modification, and overall low cost [8 , 13]. This made this gram-negative bacterium a satisfactory gene expression and commercial production platform. E. coli has contributed to the development of a variety of enzymes and proteins used industrially, for clinical applications, and biological analyses [14 –17]. However, E. coli has a lot of drawbacks, including protein expression as inclusion bodies (IBs), intracellular accumulation of proteins, endotoxin production, codon bias, protein degradation action of proteases and a lack of PTMs [2 , 13]. Many methods have been created in recent years to address these issues. The supplementation of cofactors, co-expression of the protein of interest with molecular chaperones, and the addition of fusion tags to the gene sequence, can all assist in decreasing IBs formation [9, 13]. As recently demonstrated, several tags such as -fructofuranosidase (-FFase), 30-phosphoadenosine-50-phosphatase (CysQ), and carbohydrate binding module 66 (CBM66) can aid in the production of a correctly folded and soluble protein [18 –20]. Furthermore, in silico approaches for predicting the tendency of IBs formation and then identifying proteins with the appropriate structural characteristics that can be expressed in soluble form have been established [21, 22]. Moreover, optimizing heterologous gene transcription is essential to avoid IB formation, which is an inefficient translocation/transport mechanism of produced proteins [20]. In other hands, for solving the problem of endotoxin production, endotoxin-free recombinant strain ClearColi® BL21(DE3) can be used for the synthesis of non-toxic protein [23]. Light induction of protein synthesis in E. Coli with cell autolysis can also help to secrete protein in the culture medium [24] and codon bias can be solved using host modification and codon optimization of the gene of interest [25, 26]. E. coli is well known for its inability to properly process proteins. Molecular chaperones can help with issues like incorrect disulphide binding and proteolytic degradation [27], and the intracellular accumulation of protein [14, 15]. In addition, the N-glycosylation system of Campylobacter jejuni was isolated and transferred to E. coli, enabling simple protein glycosylation [28]. Another previous study introduced individual PTMs such as phosphorylation and acetylation into one protein simultaneously used the genetic code expansion technique [29]. Some predictive models, such as the mutation predictor for increased protein expression (MPEPE), can also enhance protein expression in this system [30].

2.1.2 Bacillus subtilis

Bacillus subtilis is a Gram-positive prokaryotic cell which is widely recognized for its exceptional ability to secrete proteins and presented as a better alternative to the E. coli expression system [31]. Unlike Gram-negative bacterium which lacks an outer membrane, B. subtilis allowing proteins secretion directly into the culture medium while avoiding the production of endotoxins. Furthermore, there are no significant differences in the use of codons, and it can ease large-scale production of proper folding protein [11, 32]. Another benefit of this bacterium is its lack of toxins, which has led the US Food and Drug Administration (FDA) to declare the proteins produced by this cell factory to be generally recognized as safe (GRAS). Furthermore, what makes B. subtilis so appealing as a host cell is its classification by the European Food Safety Authority (EFSA) as having Qualified Presumptive Safety (QPS) status [32, 33]. However, as with other systems, protein production with this bacterium is challenging due to factors such as plasmid instability, the production of extracellular proteases and the presence of multiple secretion bottlenecks in the general (Sec) secretion pathway, including translocation, protein folding and membrane targeting [11, 32]. The optimization of media conditions and the combination of a signal peptide with a strong promoter can improve protein expression in this system [34]. Furthermore, using a structurally stable replicating plasmid, molecular chaperones, and signal peptides can improve translocation, folding, stability, and yield of correct folding proteins [35, 36]. Also, mediate the gene expression promotion by multiple tandem promoters can help to overexpress proteins in B. subtilis [37]. Moreover, using of strains with numerous deletions in extracellular proteases genes reduced protein degradation in this system significantly [38].

2.1.3 Streptomyces

Streptomyces are Gram-positive bacteria that live in aerobic soils and can degrade complex organic. Many strains have been used to produce recombinant proteins, but Streptomyces lividans remains the most appealing [39, 40]. Compared to Bacillus, Streptomyces can also secrete a correctly folded protein into the extracellular medium, making it easy to purify [40, 41]. However, Streptomyces are distinguished by a high proportion of guanine and cytosine in their DNA (70–73% GC), a very large genome (11.9 Mbps) [42] with gene clusters that biosynthesize diverse secondary metabolites [43]. Furthermore, Streptomyces Lividans strain has low proteolytic and restriction enzyme activities, making easy recombinant DNA insertion [40, 44]. Nevertheless, this expression system is not always efficient for certain proteins and they need optimization processes to improve their activity. By using robust and stable Streptomyces antibiotic marker-free expression system, we can enhance production of secreted proteins [45]. The Sec-dependent secretion pathway is currently used to secrete protein in Streptomyces, but the Tat-dependent pathway can also be used [46]. Unexpectedly, it has been demonstrated that Sec-dependent translocation with tatB mutant deletion, can increase protein secretion in this system [47]. Additional research is then needed to fully understand these findings. Transcriptomic and fluxomic changes, on the other hand, can help to develop a more efficient S. lividans strain allowing for the easy secretion of protein [48]. Optimization of operational conditions, screening of signal peptides, vectors, alternative promoters [39 , 50] and codon optimization [51] have been also shown as strategies to improve protein production in S. lividans.

2.2 Strategies for overexpression of protein in Eukaryotic expression hosts

2.2.1 Yeast

Because of its rapid growth, ease of gene engineering, low cost of growth medium, and ability to insert new genes, yeast has emerged as the best suitable industrial host for protein expression [11 , 52–54]. The methylotrophic Komagataella phaffii (K. phaffii) and non-methylotrophic Saccharomyces cerevisiae (S. cerevisiae) yeast expression hosts are the most promising for large-scale protein production [52, 54].

K. phaffii or Pichia pastoris is a yeast that is commonly used in pharmaceutical and biotechnological industries. Many industrially important proteins have been produced using K. phaffii [54 –57]. The most significant benefit of this host is its ability to process protein using mechanisms such as protein folding and signal peptide cleavage, intracellular PTMs and a lower degree of glycosylation [53, 54]. Indeed, the alcohol oxidase genes (AOX1 and AOX2), as well as the GAP promoter (PGAP), exhibit strong constitutive expression in the presence of glucose and glycerol, contributing significantly to K. phaffi’s reputation as an alcohol producer [58]. However, this system presents some drawbacks such as a high concentration of proteases which can degrade the product and risks associated with using of methanol as it has been shown as toxic [54, 59]. To overcome the protein degradation, several strategies have been used, including the addition of amino acids, yeast peptone, protease inhibitors, lowering the pH, and reducing the induction time and temperature during fermentation [53]. Furthermore, because controlling the concentration of methanol in the culture medium is critical for high protein yield, using glycerol or ascorbic acid/sorbitol as co-substrate in a mixture ratio with methanol could increase PAOX1 induction levels when compared to cultures with methanol only [55, 60]. On the other hand, PGCW14 promoter and PPDF promoter can be used as appropriate free methanol inducer in P. pastoris fermentations as alternative to PGAP promoter [61, 62]. Recently, a novel dual-plasmid Pichia pastoris system was developed by combining integrated PGAP and episomal PGCW14 and is able to increase protein production yield without methanol induction. Indeed, it has increased yield of XynA protein 16.7-fold and 2.86-fold, respectively, when compared to constitutive and methanol-induced expression. As methanol’s toxicity is reduced, this dual-plasmid system is very promising for use in the pharmaceutical and food industries [63]. Moreover, co-expression of transcription factor, molecular chaperones and fusion tags can increase yield of protein and reduce the intracellular aggregation of proteins in K. phaffii expression system [5 , 65].

S. cerevisiae differs from other yeast systems in that the proteins it produces are GRAS, making it an ideal host for protein production. It is non-infectious and has been used for many decades in the nutritional and biopharmaceutical industries [66]. Some marketed products derived from S. cerevisiae expression system include insulin, glucagon, macrophage, hepatitis B surface antigen, and hirudin [67, 68]. Nevertheless, some drawbacks have limited the efficiency of this system, particularly protein hyperglycosylation [54]. Indeed, the hypermannosylation capacity of S. cerevisiae can lead to reduction of heterologous glycoprotein activity. By its ability to inhibit the yeast hypermannosylation gene (OCH1) and to insert glycosyltransferase and glycosidase genes for the biosynthesis of the glycosylated protein, the GlycoSwitch® system represents a good option for solving hypermannosylation [69]. Furthermore, disrupting the activity of the essential Golgi mannosyltransferases Och1p and Mnn9p in S. cerevisiae increased protein secretion by activating the secretory pathway and affecting cell wall integrity [70]. The unfolded protein response signaling pathway is an endoplasmic reticulum (ER) stress response pathway that acts as a quality controller during secreted or membrane-localized protein synthesis. Hac1p, a key regulator of this pathway, when overexpressed, has increased xylanase production S. cerevisiae expression host [6]. Furthermore, moderate overexpression of SEC16, result of anterograde protein trafficking from the ER to the Golgi apparatus in S. cerevisiae could improve protein secretion [71]. On the other hand, the use of fittest mutated α-factor preproleader (MFα1), introduction of conserved amino acid residues into the enzyme to improve protein folding and stability, mutations by random mutagenesis of a sequence and engineering of new N-glycosylation sites in the enzyme have enhanced fungal laccase production in S. cerevisiae [72]. It has also been shown that using a secretion-enhancing peptide cassette derived from hIL-1 can strengthen production of the human granulocyte colony-stimulating factor (hG-CSF) in this system [73]. Moreover, CRISPR-associated protein 9 (Cas9) was used to create yeast platform strains by integrating a site-specific gene or deleting unwanted genes to improve protein production [52 , 75]. Metabolic pathway bottlenecks continue to be a major problem in industrial bioproduction using yeast cell factories. The HapAmp approach, as a solution, has proven to be an efficient way to eliminate metabolic bottlenecks by using haploid sufficiency as an evolutionary force and promoting gene amplification in vivo [76].

2.2.2 Mammalian cells

Mammalian cell-based expression systems are the best option for producing recombinant proteins used in disease diagnosis and treatment [77, 78]. They can introduce correct protein folding, PTMs, and product assembly, all of which are critical for the final protein’s quality (See Table 1). Furthermore, these cells can recognize the signals used to synthesize, process, and secrete eukaryotic proteins with ease and efficiency [79].

Table 1
Advantages and disadvantages of current expression systems for protein production [11 , 125]

Expression systems Advantages Disadvantages

Bacteria –Low overall cost –Lack of intron removal machinery

–Rapid production –Lack of posttranslational modifications

–Rapid growth rate –Significant protein misfolding

–Well-characterized cell lines –Nonhuman glycosylation

–High scalability –Endotoxin accumulation

–Established regulatory approvals –Codon bias

–High expression

Yeast –Simple and low-cost growing medium –Hyperglycosylation of proteins

–Appropriate post-translational modifications –Codon bias

–Rapid growth rate –Inadequate protein secretion

–No endotoxin production –Difficulty in cell disaggregation

–Guaranteed system safety

–Short production times

–High scalability

–Stable production strains

Mammalian cells –Correct folding and post-translational modifications –High cost

–Proper glycosylation –High risk of contamination with virus

–Established regulatory approvals –Unstable cell lines

–high product quality and yields –Extensive production timeframe

–Complicated technology

Insect cells –High expression –Expensive and time consuming

–Correct folding and post-translational modifications –No optimum growth conditions

–Proper glycosylation –Unwanted posttranslational changes

–Existing regulatory approval –Nonhumans glycosylation

–High scalability

Transgenic animals –Extensive scaling potential –A longer production periods

–Proper protein folding –Regulatory and ethical concerns

–Appropriate posttranslational modifications –Inadequately characterized expression system

–Long-lasting cell lines –Higher cost

–Established regulatory approvals

Transgenic plants –Quick and inexpensive –Limited glycosylation capacity

–Optimum growth conditions –No regulatory approval

–Low cost of scaling up –Target-dependent expression levels

–Free of pathogen contamination

–Production of complex proteins

–Economical

Expression systems	Advantages	Disadvantages
Bacteria	–Low overall cost	–Lack of intron removal machinery
	–Rapid production	–Lack of posttranslational modifications
	–Rapid growth rate	–Significant protein misfolding
	–Well-characterized cell lines	–Nonhuman glycosylation
	–High scalability	–Endotoxin accumulation
	–Established regulatory approvals	–Codon bias
	–High expression
Yeast	–Simple and low-cost growing medium	–Hyperglycosylation of proteins
	–Appropriate post-translational modifications	–Codon bias
	–Rapid growth rate	–Inadequate protein secretion
	–No endotoxin production	–Difficulty in cell disaggregation
	–Guaranteed system safety
	–Short production times
	–High scalability
	–Stable production strains
Mammalian cells	–Correct folding and post-translational modifications	–High cost
	–Proper glycosylation	–High risk of contamination with virus
	–Established regulatory approvals	–Unstable cell lines
	–high product quality and yields	–Extensive production timeframe
	–Complicated technology
Insect cells	–High expression	–Expensive and time consuming
	–Correct folding and post-translational modifications	–No optimum growth conditions
	–Proper glycosylation	–Unwanted posttranslational changes
	–Existing regulatory approval	–Nonhumans glycosylation
	–High scalability
Transgenic animals	–Extensive scaling potential	–A longer production periods
	–Proper protein folding	–Regulatory and ethical concerns
	–Appropriate posttranslational modifications	–Inadequately characterized expression system
	–Long-lasting cell lines	–Higher cost
	–Established regulatory approvals
Transgenic plants	–Quick and inexpensive	–Limited glycosylation capacity
	–Optimum growth conditions	–No regulatory approval
	–Low cost of scaling up	–Target-dependent expression levels
	–Free of pathogen contamination
	–Production of complex proteins
	–Economical

Protein of industrial interest have been produced using a variety of mammalian cell lines [80 –83]. The Chinese hamster ovary (CHO) cell line is the most commonly used among other cell lines, followed by human embryonic kidney (HEK), mouse myeloma (NS0), mouse myeloma (SP2/0), and baby hamster kidney (BHK-21) [84, 85]. A recent study found that CHO cell-based systems contribute 84% of approved monoclonal antibodies (mAb) [86]. However, industrial protein production using this system is currently hampered by high costs, complicated technology, and the risk of contamination with animal viruses [11]. Because the CHO cell line can be grown at high cell densities in serum-free and chemically defined media and has a low risk of infection with animal viruses, it can be used to generate a safety protein [87]. It’s the case of the recombinant fusion protein of the Fc domain of the human tumour necrosis factor receptor - IgG1, which has been successfully produced in genetically modified CHO-DG44 cells and is being presented as a new therapeutic strategy for cytokine-mediated diseases [88]. Furthermore, mitochondrial membrane potential-enriched CHO hosts have been presented as an innovative and powerful tool for improving bioproduction capacity, outperforming the parental host in terms of long-term cell viability, fed batch productivity, lactate metabolism, and cell cloning efficiency during the generation of monoclonal cell lines [89].

In another study, the use of appropriate protein secretion signaling sequences, fusion tags, and expression vectors has proven beneficial in increasing the yield of proteins purified from mammalian cell lines [90]. Promoters are required for transcriptional signal integration and processing. As a result, using the correct promoter, optimizing the combination of promoter and different regulatory elements, and avoiding promoter methylation can all strengthen the protein’s stability and expression [91]. This is the case with the Hspa5 promoter, which has been identified as a powerful promoter for increasing monoclonal antibody production per cell at a late stage of culture [92]. Moreover, optimization of culture process as well as codon optimization can be used as strategies to improve protein yields in mammalian system [93].

CRISPR and other gene editing tools have been used successfully to improve mammalian expression system product quality [94, 95]. The function of the ARC gene was investigated in vitro in a recent study by creating an ARC-knockout (KO) HEK293 cell line via CRISPR/Cas9-mediated gene editing [96]. Some CHO cell lines have been engineered to resist apoptosis in order to increase protein yield. Many variables, however, disrupt the kinetics that govern cell fate in bioreactors. Using knockouts of three BCL2 family effector proteins, Bak1, Bax, and Bok, CRISPR/Cas9 was effective in modelling apoptosis resistance in CHO cells [97]. Another study found that a newly discovered CRISPR/Cas12a-based synthetic transcription factor induced multiplexed activation in mammalian cells and upregulated gene expression [98]. Furthermore, CRISPR/Cas13a is a versatile platform that can be modified for RNA silencing and binding in mammalian cells [99].

2.2.3 Transgenic plants

Recombinant proteins, including vaccines, antibodies, antigens, growth factors, cosmetic ingredients, enzymes and research or diagnostic reagents, have been produced using transgenic plants. We’ve been talking about plant molecular farming concept for over a decade, which describes the production of protein of industrial interest using plants as host platforms [100 –103]. Plant-based expression systems have several advantages, including low cost, well-understood production processes, high scalability, the ability to combine complex proteins with eukaryotic PTMs, and a low risk of infection by animal pathogens [12 , 105]. Recently, edible vaccines, a new vaccine concept that can replace traditional vaccines and has the unique ability to combine medical science and plant biology, have been developed. These conventional vaccines are made up of pathogens with reduced virulence that have the ability to replicate in the host plant, such as maize, rice, and potatoes [106 –108]. They have several advantages, including the ability to elicit mucosal immunity, performing method of immunization without needing sterile injections, storage as seed for years, no need for adjuvants to elicit an immune response, and no reverse virulence [106 , 109]. Nevertheless, current challenges of this system include a lack of non-human glycosylation and regulatory approval [12, 100]. Then using stronger vectors and promoters, engineering glycosylation and sialylation, codon optimization, fusion tags and signal sequences can enhance the production of a correct folded human glycosylated protein in this system [110].

2.2.4 Transgenic animals

Transgenic animal technologies have used genetic engineering to insert epigenetic genes into the animal genome, allowing these genes to be inherited and expressed by offspring. Its effectiveness is dependent on two factors: the transport of this DNA across the nuclear membrane to the chromosomes and the transport of the DNA across the recipient cell’s plasma membrane. Transgenic efficiency and precise control of gene expression are two factors that can limit the success of animal transgenesis [111]. Seminal plasma, mammary gland, egg white, urine, blood, and silkworm cocoon are all examples of transgenic animal systems. Because of its high level of expression and ability to introduce PTMs, the mammary gland is considered an excellent system for recombinant protein biosynthesis. Moreover, the rabbit is the most suitable for protein production among all the other mammalian species currently being studied as bioreactors (pig, goat, sheep, and cow) [112]. Some authors, however, have highlighted promising methodologies that favor the use of transgenic cattle as bioreactors for the production of protein in milk for industrial use [113]. Furthermore, significant advances in genome editing over the last decade, such as the use of the CRISPR/Cas9 system, have greatly simplified animal transgenesis, allowing for the development of new approaches to animal production, including economically important species such as milk [114]. The advantages and disadvantages of various expressions systems used for recombinant protein production is given in Table 1.

2.2.5 Insect cells

Insect cells-based expression systems have been used to produce recombinant proteins important in vaccination, diagnosis and treatments of many diseases [17 , 116]. BEVS (baculovirus expression vector system) is a tool for protein production in insect cells that was developed through baculovirus genetic engineering. Co-transfection of a plasmid with a linearized, non-infectious autotrophic plant multinucleopolyhedrosis virus (AcMNPV) result in the production of recombinant BEVS [115].

Compared to other systems, BEVS has many advantages such as providing a correct folding protein with a disulphide bridge and introducing PTMs, very important for protein function. Furthermore, because the baculovirus genome can insert DNA fragments of up to 34 kbp, using a strong viral promoter increases the system’s protein yield [116]. However, protein N-glycosylation in insect cells differs from that in mammalian cells, which can result in a significant reduction of protein biological activity [117]. The development of humanized insect cells and the modification of the baculoviral genome to form the SweetBac system can allow the expression of mammalian glycosylating enzymes and overcome this problem [118, 119].

Baculoviruses are typically propagated in insect cell lines called Sf9. Furthermore, recombinant proteins were also successfully expressed in S2, Sf21 and Tn-368, as they grow quickly and tolerate stress [94, 120]. However, a stable master clone High-Five^trademark cell line was recently created for the first time by combining RMCE with Flipase (Flp) and fluorescence-activated cell sorting (FACS). Unlike other cells, these cells can express single or multiple proteins of interest from tagged genomic loci, which aids in the development of biological therapies [121]. Furthermore, MultiBac, a recently developed advanced baculovirus-insect cell system, is efficient for heterologous multigene transfer and multiprotein complex production [122]. In addition, BEVS, which is commercially available and similar to BaculoDirect, is a gateway technology that uses a site-specific recombination system of bacteriophage lambda and is simple to integrate [123]. This improved MultiBac system was used in another study to express high levels of VP2 protein and efficiently purify canine microviruses, stimulating the production of high levels of hemagglutination inhibitory antibodies in mice [124]. Moreover, an extended process for the continuous production of Gag virus-like particles (VLPs) in high cell density pseudotypes (haemagglutinin influenza, HA) using stable insect cells adapted to low-temperature culture has also been established. It is regarded as an appealing alternative platform to the insect cell-baculovirus expression vector system (IC-BEVS) [125]. Meanwhile, a novel baculovirus surface presentation system was developed to efficiently present the S proteins of SARS-CoV and SARS-CoV-2 on the surface of recombinant baculoviruses. Indeed, it can transduce HEK 293T cells overexpressing ACE2 receptors with higher transduction efficiency [126]. It has also been proved that RNAi technology, enhancer optimization, co-expression of chaperone proteins (Hsp40, PDI, and Hsc70), and promoter can increase the production of folded proteins in this system [123].

CRISPR-Cas9 technology allows for specific genetic modifications to further improve and expand the BEVS platform’s suitability for recombinant protein production [123]. When compared to the original Drosophila melanogaster CRISPR/Cas9 plasmid, a Culex-optimized CRISPR/Cas9 plasmid efficiently edited the RNAi proteins Dicer-2 and PIWI4 genomic locus in the Hsu cell line [127]. This technology has also been used to create transgenic Cas9 cell lines for future research, including knock-in and multi-threaded editing [128]. Moreover, CRISPR/Cas9 has been used to create single baculovirus vectors as well as single and multiple master editing kits capable of performing cleavage-free DNA search and replacement interventions with no detectable imprinting [129].

3 Conclusion

Recombinant proteins are very useful in clinical, food, and biopharmaceutical industries. E. coli is the simplest and least expensive system for protein production but Gram-positive bacteria, such as Bacillus and Streptomyces, are also suitable alternative hosts due to their ability to secrete proteins directly in growth medium, while reducing purification steps. As proteins produced by yeast especially S. Cerevisiae are GRAS, added to their capacity to introduce PTMs, these hosts are most used for the production of complex and safety proteins compared to others. Moreover, current limitations of these expression systems can be addressed through bioengineering approaches including HapAmp, GlycoSwitch system, use of strong promoters and plasmids, co-expression of transcription factors, molecular chaperones, and fusion tags. Some technologies like the editing tool CRISPR and MPEPE have been shown to be important in disrupting unwanted genes, predicting misfolding of protein, and engineering apoptosis-resistant cells for optimization of protein biological activity. However, these strategies are still ineffective in producing large quantities of recombinant proteins to meet the market’s ever-increasing demand. Therefore, more funds should be allocated by policymakers to research institutes working on recombinant protein production, as well as the collaboration of expert researchers in the field from around the world to achieve meaningful results.

Conflict of interest

The authors have no conflict of interest to report.

References

Butenas

Comparison of natural and recombinant tissue factor proteins: new insights, bchm 2013;394(7):819–29.

Golam Reza

, Jalali-Javaran

Selecting appropriate hosts for recombinant proteins production, Hormozgan Med J 2016;20(3):214–22.

Browning

, Richards

, Peswani

, Roobol

, Busby

SJW

, Robinson

Escherichia coli “TatExpress” strains super-secrete human growth hormone into the bacterial periplasm by the Tat pathway, Biotechnol Bioeng 2017;114(12):2828–36.

Hamed

, Karamanou

, Ólafsdottir

, Basílio

JSM

, Simoens

, Tsolis

, et al. Large-scale production of a thermostable Rhodothermus marinus cellulase by heterologous secretion from Streptomyces lividans, Microb Cell Factories 2017;16(1):232.

Zirpel

, Degenhardt

, Zammarelli

, Wibberg

, Kalinowski

, Stehle

, et al. Optimization of Δ9-tetrahydrocannabinolic acid synthase production in Komagataella phaffii via post-translational bottleneck identification, J Biotechnol 2018;272:40–7.

Bao

, Li

, Chen

, Sun

, Wang

, Chen

, et al. Expression and function of an Hac1-regulated multi-copy xylanase gene in Saccharomyces cerevisiae, Sci Rep 2020;10:11686.

Aricescu

, Lu

, Jones

A time- and cost-efficient system for high-level protein production in mammalian cells, Acta Crystallogr D Biol Crystallogr 2006;62(10):1243–50.

Terpe

Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems, Appl Microbiol Biotechnol 2006;72(2):211–22.

Rosano

, Ceccarelli

Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol [Internet]. 2014 Apr 17 [cited 2022 Jul 29];5. Available from: https://journal.frontiersin.org/article/10.3389/fmicb.2014.00172/abstract.

10.

Zirpel

, Stehle

, Kayser

Production of Δ9-tetrahydrocannabinolic acid from cannabigerolic acid by whole cells of Pichia (Komagataella) pastoris expressing Δ9-tetrahydrocannabinolic acid synthase from Cannabis sativa L, Biotechnol Lett 2015;37(9):1869–75.

11.

Gomes

, Byregowda

SBMV

, Vinayagamurthy

An Overview of Heterologous Expression Host Systems for the Production of Recombinant Proteins, Adv Anim Vet Sci 2016;4:346–56.

12.

Burnett

MJB

, Burnett

Therapeutic recombinant protein production in plants: Challenges and opportunities, PLANTS PEOPLE PLANET 2020;2(2):121–32.

13.

Rosano

, Morales

, Ceccarelli

New tools for recombinant protein production in Escherichia coli: A 5-year update, Protein Sci 2019;28(8):1412–22.

14.

, Zhang

Extracellular expression of Aerococcus viridans pyruvate oxidase in recombinant Escherichia coli through SecB co-expression, RSC Adv 9(45):26291–301.

15.

Zhang

, Lu

, Zhang

, Liu

, Pang

, Lv

Development an effective system to expression recombinant protein in E, coli via comparison and optimization of signal peptides: Expression of Pseudomonas fluorescens BJ-10 thermostable lipase as case study. Microb Cell Factories 2018;17:50.

16.

Kanno

, Leite de

LCC

, Pereira

, de Jesus

MJR

, Andreata-Santos

, Alvesdos

RPS

, et al. Optimization and scale-up production of Zika virus ΔNS1 in Escherichia coli: application of Response Surface Methodology, AMB Express 2019;10:1.

17.

Cid

, Bolívar

Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies, Biomolecules 2021;11(8):1072.

18.

Chen

, Sun

, Li

, Yan

, Xu

, Chen

, et al. A fusion protein strategy for soluble expression of Stevia glycosyltransferase UGT76G1 in Escherichia coli, 3 Biotech 2017;7(6):356.

19.

Cheng

, Wu

, Cui

, Wu

, Jiang

, He

A novel Ffu fusion system for secretory expression of heterologous proteins in Escherichia coli, Microb Cell Factories 2017;16:231.

20.

, Kang

, Kim

, Yi

, Kang

, Bae

, et al. A novel protein fusion partner, carbohydrate-binding module family 66, to enhance heterologous protein expression in Escherichia coli, Microb Cell Factories 2021;20:232.

21.

Behravan

, Hashemi

RSM-based Model to Predict Optimum Fermentation Conditions for Soluble Expression of the Antibody Fragment Derived from 4D5MOC-B Humanized Mab in SHuffle^TM T7 E, coli. Iran J Pharm Res IJPR 2021;20(1):254–66.

22.

Karaiyan

, Chang

CCH

, Chan

, Tey

, Ramanan

, Ooi

In silico screening and heterologous expression of soluble dimethyl sulfide monooxygenases of microbial origin in Escherichia coli, Appl Microbiol Biotechnol 2022;106(12):4523–37.

23.

Cardoso

, Paredes

SAH

, Campani

, Goncalves

, Zangirolami

ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification, Appl Microbiol Biotechnol 2022;106(3):1011–29.

24.

Chang

, Zhang

, Pan

, Lu

, Fang

, et al. Light induced expression of β-glucosidase in Escherichia coli with autolysis of cell, BMC Biotechnol 2017;17:74.

25.

Claassens

, Siliakus

, Spaans

, Creutzburg

SCA

, Nijsse

, Schaap

, et al. Improving heterologous membrane protein production in Escherichia coli by combining transcriptional tuning and codon usage algorithms, PLoS One 2017;12(9):e0184355.

26.

Gupta

, Shukla

Advanced technologies for improved expression of recombinant proteins in bacteria: perspectives and applications, Crit Rev Biotechnol 2016;36(6):1089–98.

27.

Gawin

, Ertesvåg

, Hansen

SAH

, Malmo

, Brautaset

Translational regulation of periplasmic folding assistants and proteases as a valuable strategy to improve production of translocated recombinant proteins in Escherichia coli, BMC Biotechnol 2020;20:24.

28.

Valderrama-Rincon

, Fisher

, Merritt

, Fan

, Reading

, Chhiba

, et al. An engineered eukaryotic protein glycosylation pathway in Escherichia coli, Nat Chem Biol 2012;8(5):434–6.

29.

Venkat

, Sturges

, Stahman

, Gregory

, Gan

, Fan

Genetically Incorporating Two Distinct Post-translational Modifications into One Protein Simultaneously, ACS Synth Biol 2018;7(2):689–95.

30.

Ding

, Guan

, Xu

, Wang

, Yan

, Zhang

, et al. MPEPE, a predictive approach to improve protein expression in E, coli based on deep learning. Comput Struct Biotechnol J 2022;20:1142–53.

31.

de Souza

, Guimarães

, Pereira dos

, Mariúba

LAM

Themultifunctionality of expression systems in Bacillus subtilis:Emerging devices for the production of recombinant proteins, ExpBiol Med 2021;246(23):2443–53.

32.

Neef

, van Dijl

, Buist

Recombinant protein secretion by Bacillus subtilis and Lactococcus lactis: pathways, applications, and innovation potential, Essays Biochem 2021;65(2):187–95.

33.

, SONG

, LIU

, YU

, SHANG

, TANG

, et al. Application of Bacillus subtilis as a live vaccine vector: A review, J Vet Med Sci 2020;82(11):1693–9.

34.

Hanif

, Gul

, Hanif

, Hashmi

Heterologous Secretory Expression and Characterization of Dimerized Bone Morphogenetic Protein 2 in Bacillus subtilis, BioMed Res Int 2017;2017:9350537.

35.

Heinrich

, Drewniok

, Neugebauer

, Kellner

, Wiegert

The YoaW signal peptide directs efficient secretion of different heterologous proteins fused to a StrepII-SUMO tag in Bacillus subtilis, Microb Cell Factories 2019;18:31.

36.

Quesada-Ganuza

, Antelo-Varela

, Mouritzen

, Bartel

, Becher

, Gjermansen

, et al. Identification and optimization of PrsA in Bacillus subtilis for improved yield of amylase, Microb Cell Factories 2019;18:158.

37.

Liu

, Zheng

, Ge

, Cui

, Zhou

High-level extracellular production of recombinant nattokinase in Bacillus subtilis WB800 by multiple tandem promoters, BMC Microbiol 2019;19:89.

38.

Pohl

, Bhavsar

, Hulme

, Bloor

, Misirli

, Leckenby

, et al. Proteomic analysis of Bacillus subtilis strains engineered for improved production of heterologous proteins, Proteomics 2013;13(22):3298–308.

39.

Berini

, Marinelli

, Binda

Streptomycetes: Attractive Hosts for Recombinant Protein Production, Front Microbiol 2020;11:1958.

40.

Anné

, Economou

, Bernaerts

Protein Secretion inGram-Positive Bacteria: From Multiple Pathways to Biotechnology, Curr Top Microbiol Immunol 2017;404:267–308.

41.

Hwang

, Lee

, Kim

, et al. Streptomyces as Microbial Chassis for Heterologous Protein Expression, Front Bioeng Biotechnol 2021;9:804295.

42.

Wang

, Yan

, Zhang

, An

, Wang

, Tian

, et al. Genome Sequence of the Milbemycin-Producing Bacterium Streptomyces bingchenggensis, J Bacteriol 2010;192(17):4526–7.

43.

Nett

, Ikeda

, Moore

Genomic basis for natural product biosynthetic diversity in the actinomycetes, Nat Prod Rep 2009;26(11):1362.

44.

Anné

, Vrancken

, Van Mellaert

, Van Impe

, Bernaerts

Protein secretion biotechnology in Gram-positive bacteria withspecial emphasis on Streptomyces lividans, Biochim Biophys Acta 2014;1843(8):1750–61.

45.

Sevillano

, Díaz

, Santamaría

Development of an antibiotic marker-free platform for heterologous protein production in Streptomyces, Microb Cell Factories 2017;16:164.

46.

Goosens

, Monteferrante

, van Dijl

The Tat system of Gram-positive bacteria, Biochim Biophys Acta BBA - Mol Cell Res 2014;1843(8): 1698–706.

47.

Schaerlaekens

, Van Mellaert

, Lammertyn

, Geukens

, Anné

The importance of the Tat-dependent protein secretion pathway inStreptomyces as revealed by phenotypic changes in tat deletionmutants and genome analysis, Microbiology 2004;150(1):21–31.

48.

Daniels

, Bouvin

, Busche

, Rückert

, Simoens

, Karamanou

, et al. Transcriptomic and fluxomic changes in Streptomyces lividans producing heterologous protein, Microb Cell Factories 2018;17:198.

49.

Gabarró

, Gullón

, Vicente

, Caminal

, Mellado

, López-Santín

A Streptomyces lividans SipY deficient strain as a host for protein production: standardization of operational alternatives for model proteins: Streptomyces protein production, J Chem Technol Biotechnol 2017;92(1):217–23.

50.

Sevillano

, Vijgenboom

, van Wezel

, Díaz

, Santamaría

New approaches to achieve high level enzyme production in Streptomyces lividans, Microb Cell Factories 2016;15(1):28.

51.

Liu

, Wang

, Du

, Chen

Improving the active expression of transglutaminase in Streptomyces lividans by promoter engineering and codon optimization, BMC Biotechnol 2016;16(1):75.

52.

Tripathi

, Shrivastava

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development, Front Bioeng Biotechnol 2019;7:420.

53.

Liu

, Yang

, Shin dong

, Chen

, Li

, Du

, et al. How to achieve high-level expression of microbial enzymes: Strategies and perspectives, Bioengineered 2013;4(4):212–23.

54.

Baghban

, Farajnia

, Rajabibazl

, Younes

, Mafi

, Hoseinpoor

, et al. Yeast Expression Systems: Overview and Recent Advances. Mol Biotechnol. 2019;61.

55.

Bustos

, Quezada

, Veas

, Altamirano

, Braun-Galleani

, Fickers

, et al. Advances in Cell Engineering of the Komagataella phaffii Platform for Recombinant Protein Production, Metabolites 2022;12(4):346.

56.

, Zhang

, Wu

, Chen

, Liu

Characterization of a highly stable α-galactosidase from thermophilic Rasamsonia emersonii heterologously expressed in a modified Pichia pastoris expression system, Microb Cell Factories 2019;18:180.

57.

Bolghari

, Shahsavarani

, Anvari

, Habibollahi

A novel recombinant chimeric bio-adhesive protein consisting of mussel foot protein 3, 5, gas vesicle protein A, and CsgA curli protein expressed in Pichia pastoris, AMB Express 2022;12:23.

58.

TürkanogluÖzçelik

, Yılmaz

, Inan

Pichia pastoris Promoters. In: Gasser B, Mattanovich D, editors. Recombinant Protein Production in Yeast [Internet]. New York, NY: Springer New York; 2019 [cited 2022 Oct 26]. pp. 97-112. (Methods in Molecular Biology; vol. 1923). Available from: https://link-springer-com-443.web.bisu.edu.cn/10.1007/978-1-4939-9024-53.

59.

Jia

, Li

, Wu

, Li

, Huang

Enhanced human lysozyme production by Pichia pastoris via periodic glycerol and dissolved oxygen concentrations control, Appl Microbiol Biotechnol 2021;105(3):1041–50.

60.

Azadi

, Sadjady

, Mortazavi

, Naghdi

, Mahboubi

, Solaimanian

Bioprocess and downstream optimization of recombinant human growth hormone in Pichia pastoris, Res Pharm Sci 2018;13(3):222–38.

61.

Liang

, Zou

, Lin

, Zhang

, Ye

Identification and characterization of P GCW a novel, strong constitutive promoter of Pichia pastoris, Biotechnol Lett 2013;35(11):1865–71.

62.

Garrigós-Martínez

, Vuoristo

, Nieto-Taype

, Tähtiharju

, Uusitalo

, Tukiainen

, et al. Bioprocess performance analysis of novel methanol-independent promoters for recombinant protein production with Pichia pastoris, Microb Cell Factories 2021;20(1):74.

63.

Xia

, Hu

, Pan

, Wu

Improved Production of Streptomyces sFA1 Xylanase in a Dual-Plasmid Pichia pastoris System, Curr Issues Mol Biol 2021;43(3):2289–304.

64.

Cui

, Huang

, Zhang

, Wang

, Qin

, Tu

,et al. Recombinant expression of hen egg white lysozyme with the assistance of xylanase fusion partner in Pichia pastoris, Bioengineered 13(5):13860–71.

65.

Deng

, Li

, Ma

, Zhao

, Ming

, Lu

, et al. Co-expressing GroEL–GroES, Ssa1–Sis1 and Bip–PDI chaperones for enhanced intracellular production and partial-wall breaking improved stability of porcine growth hormone, Microb Cell Factories 2020;19:35.

66.

Llopis

, Hernández-Haro

, Monteoliva

, Querol

, Molina

, Fernández-Espinar

Pathogenic potential of Saccharomycesstrains isolated from dietary supplements, PloS One 2014;9(5):e98094.

67.

Demain

, Vaishnav

Production of recombinant proteins by microbes and higher organisms, Biotechnol Adv 2009;27(3):297–306.

68.

Nielsen

Production of biopharmaceutical proteins by yeast: advances through metabolic engineering, Bioengineered 2013;4(4):207–11.

69.

Laukens

, De Wachter

, Callewaert

Engineering the Pichia pastoris N-Glycosylation Pathway Using the GlycoSwitch Technology. Glyco-Eng. 2015;103-22.

70.

Tang

, Wang

, Song

, Xu

, Zhang

, et al. N-hypermannose glycosylation disruption enhances recombinant protein production by regulating secretory pathway and cell wall integrity in Saccharomyces cerevisiae, Sci Rep 2016;6:25654.

71.

Bao

, Huang

, Petranovic

, Nielsen

Balanced trafficking between the ER and the Golgi apparatus increases protein secretion in yeast, AMB Express 2018;8:37.

72.

Aza

, de Salas

, Molpeceres

, Rodríguez-Escribano

, de la Fuente

, Camarero

Protein Engineering Approaches to Enhance Fungal Laccase Production in S, cerevisiae. Int J Mol Sci 2021;22(3):1157.

73.

Cho

, Oh

, Jang

, Kim

, Song

, et al. Synthetic propeptide design to enhance the secretion of heterologous proteins by Saccharomyces cerevisiae, MicrobiologyOpen 2022;11(3):e1300.

74.

Wang

, Li

, Chen

, Siewers

CRISPR/Cas9-mediated point mutations improve α-amylase secretion in Saccharomyces cerevisiae, FEMS Yeast Res.foac 2022;22(1):033.

75.

Gast

, Sandegren

, Dunås

, Ekblad

, Güler

, Thorén

, et al. Engineering Saccharomyces cerevisiae for the production and secretion of Affibody molecules, Microb Cell Factories 2022;21:36.

76.

Peng

, Esquirol

, Lu

, Shen

, Cheah

, Howard

, et al. An in vivo gene amplification system for high level expression in Saccharomyces cerevisiae, Nat Commun 2022;13:2895.

77.

Mark

JKK

, Lim

CSY

, Nordin

, Tye

Expression of mammalian proteins for diagnostics and therapeutics: a review, Mol Biol Rep 2022;49(11):10593–608.

78.

Coulet

, Kepp

, Kroemer

, Basmaciogullari

Metabolic Profiling of CHO Cells during the Production of Biotherapeutics, Cells 2022;11(12):1929.

79.

Khan

Gene expression in Mammalian cells and its applications, Adv Pharm Bull 2013;3(2):257–63.

80.

Lü

, Zhou

, Zhu

, Zhou

, Huang

, Zhang

, et al. [Construction and identification of a HEK293 cell line with stable TrxR1 overexpression], Nan Fang Yi Ke Da Xue Xue Bao 2022;42(4):554–60.

81.

Luthra

, Cheema

, Whitney

, Bakker

WAM

, Sandalon

, Richardson

, et al. Stable, high yield expression of gp145 Env glycoprotein from HIV-1 in mammalian cells, Biol J Int Assoc Biol Stand 2021;73:16–23.

82.

Ryu

, Kim

, Park

, Kim

, Jeong

Development of a CHO cell line for stable production of recombinant antibodies against human MMP9, BMC Biotechnol 2022;22(1):8.

83.

Strasser

, Boi

, Guapo

, Donohue

, Barron

, Rainbow-Fletcher

, et al. Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells, Int J Mol Sci 2021;22(21):11499.

84.

Demirhan

, Kumar

, Zhu

, Poulsen

, Majewska

, Sebastian

, et al. Comparative systeomics to elucidate physiological differences between CHO and SP2/0 cell lines, Sci Rep 2022;12(1):3280.

85.

Malm

, Kuo

, Barzadd

, Mebrahtu

, Wistbacka

, Razavi

, et al. Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins, Metab Eng 2022;72:171–87.

86.

Walsh

Biopharmaceutical benchmarks Nat Biotechnol

2018;36(12):1136–45.

87.

Kim

, Kim

, Lee

CHO cells in biotechnology for production of recombinant proteins: current state and further potential, Appl Microbiol Biotechnol 2012;93(3):917–30.

88.

Thao Thi Thanh Nguyen , Giang Huong Ta , Le Thi Thu Le , Thao Thanh Nguyen Vo , Tram Thi Kim Pham , Quan Dang Nguyen Production of recombinant human tumor necrosis factor receptor- IgG1 Fc domain fusion protein expressed by genetically CHO- DG44 cells, Journal of Cellular Biotechnology 2022;8(2):51–66.

89.

Chakrabarti

, Chaerkady

, Wang

, Weng

SHS

, Wang

, Qian

, et al. Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability, mAbs 2022;14(1):2020081.

90.

Dalton

, Barton

Over-expression of secreted proteins from mammalian cell lines, Protein Sci 2014;23(5):517–25.

91.

, Fan

, Wang

Factors Affecting the Expression of Recombinant Protein and Improvement Strategies in Chinese Hamster Ovary Cells. Front Bioeng Biotechnol [Internet]. 2022 [cited 2022 Nov 9];10. Available from: https://www.frontiersin.org/articles/10.3389/fbioe.2022.880155.

92.

Tanemura

, Masuda

, Okumura

, Takagi

, Kajihara

, Kakihara

, et al. Development of a stable antibody production system utilizing an Hspa5 promoter in CHO cells, Sci Rep 2022;12(1):7239.

93.

, Fan

, Wang

Factors Affecting the Expression of Recombinant Protein and Improvement Strategies in Chinese Hamster Ovary Cells, Front Bioeng Biotechnol 2022;10:880155.

94.

Tripathi

, Shrivastava

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development, Front Bioeng Biotechnol 2019;7:420.

95.

Giuliano

, Lin

, Girish

, Sheltzer

Generating Single Cell-Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9, Curr Protoc Mol Biol 2019;128(1):e100.

96.

Wang

, Hsu

, Tsai

, Cheng

Transcriptomic and Proteomic Analysis of CRISPR/Cas9-Mediated ARC-Knockout HEK293 Cells, Int J Mol Sci 2022;23(9):4498.

97.

MacDonald

, Barry

, Groves

, Martínez

, Gray

, Baker

, et al. Modeling apoptosis resistance in CHO cells with CRISPR-mediated knockouts of Bak1, Bax, and Bok, Biotechnol Bioeng 2022;119(6):1380–91.

98.

Bryson

, Auxillos

, Rosser

Multiplexed activation in mammalian cells using a split-intein CRISPR/Cas12a based synthetic transcription factor, Nucleic Acids Res 2022;50(1):549–60.

99.

Cox

DBT

, Gootenberg

, Abudayyeh

, Franklin

, Kellner

, Joung

, et al. RNA editing with CRISPR-Cas13, Science 2017;358(6366):1019–27.

100.

Shanmugaraj

, Bulaon

CJ I

, Phoolcharoen

Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production, Plants 2020;9(7):842.

101.

Chahardoli

, Fazeli

, Niazi

, Ghabooli

Recombinant expression of LFchimera antimicrobial peptide in a plant-based expression system and its antimicrobial activity against clinical and phytopathogenic bacteria, Biotechnol Biotechnol Equi 2018;32(3):714–23.

102.

Rattanapisit

, Chao

, Siriwattananon

, Huang

, Phoolcharoen

Plant-Produced Anti-Enterovirus 71 (EV71) Monoclonal Antibody Efficiently Protects Mice Against EV71 Infection, Plants 2019;8(12):560.

103.

Schillberg

, Finnern

Plant molecular farming for the production of valuable proteins - Critical evaluation of achievements and future challenges, J Plant Physiol. 258- 2021;259:153359.

104.

Ayan

, Meric

, Gümüs

, Atak

Next Generation of Transgenic Plants: From Farming to Pharming. In: Sithole Niang I, editor. Genetically Modified Plants and Beyond [Internet]. IntechOpen; 2022 [cited 2022 Nov 10]. Available from: https://www.intechopen.com/chapters/80206

105.

Nosaki

, Hoshikawa

, Ezura

, Miura

Transient protein expression systems in plants and their applications, Plant Biotechnol Tokyo Jpn 2021;38(3):297–304.

106.

Pascual

Vaccines are for dinner, Proc Natl Acad Sci U S A 2007;104(26):10757–8.

107.

Nochi

, Takagi

, Yuki

, Yang

, Masumura

, Mejima

, et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination, Proc Natl Acad Sci U S A 2007;104(26):10986–91.

108.

Zhou

, Gong

, Li

, Yang

, Guan

, Zhou

, et al. Expression of Helicobacter pylori urease B on the surface of Bacillus subtilis spores, J Med Microbiol 2015;64(1):104–10.

109.

Kurup

, Thomas

Edible Vaccines: Promises and Challenges, Mol Biotechnol 2020;62(2):79–90.

110.

Sethi

, Kumari

, Dey

Engineering of Plants for Efficient Production of Therapeutics, Mol Biotechnol 2021;63(12):1125–37.

111.

Kumar

, Yadav

, Singh

, Vandre

, Singh

, Verma

, et al. Transgenic animal technology: Recent advances and applications: A Review, Agric Rev 2015;36(1):46.

112.

Wang

, Zhao

, Bai

, Fan

, Liu

Expression Systems and Species Used for Transgenic Animal Bioreactors, BioMed Res Int 2013)580463.

113.

Monzani

, Adona

, Ohashi

, Meirelles

, Wheeler

Transgenic bovine as bioreactors: Challenges and perspectives, Bioengineered 2016;7(3):123–31.

114.

Shepelev

, Kalinichenko

, Deykin

, Korobko

Production of Recombinant Proteins in the Milk of Transgenic Animals: Current State and Prospects, Acta Naturae 2018;10(3):40–7.

115.

Kumar

, Pandey

, Halder

Preventive, Diagnostic and Therapeutic Applications of Baculovirus ExpressionVector System. Trends Insect Mol Biol Biotechnol. 2017;163-91.

116.

Fabre

, Arrías

, Masson

, Pidre

, Romanowski

Baculovirus-Derived Vectors for Immunization and Therapeutic Applications. Emerg Reemerging Viral Pathog. 2020;197-224.

117.

Harrison

, Jarvis

Transforming Lepidopteran Insect Cells for Continuous Recombinant Protein Expression. In: Murhammer DW, editor. Baculovirus and Insect Cell Expression Protocols [Internet]. New York, NY: Springer New York; 2016 [cited 2022 Nov 24]. pp. 329-48. (Methods in Molecular Biology; vol. 1350). Available from: https://link-springer-com-443.web.bisu.edu.cn/10.1007/978-1-4939-3043-216

118.

Mabashi-Asazuma

, Kuo

, Khoo

, Jarvis

A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells, Glycobiology 2014;24(3):325–40.

119.

Palmberger

, Wilson

IBH

, Berger

, Grabherr

, Rendic

SweetBac: a new approach for the production of mammalianised glycoproteins in insect cells, PloS One 2012;7(4):e34226.

120.

Correia

, Fernandes

, Castro

, Nagaoka

, Takashima

, Tsuboi

, et al. Asexual Blood-Stage Malaria Vaccine Candidate PfRipr Enhanced Production in Insect Cells, Front Bioeng Biotechnol 2022;10:908509.

121.

Dias

, Vidigal

, Sequeira

, Alves

, Teixeira

, Roldão

Insect High Five^TM cell line development using site-specific flipase recombination technology, G3 GenesGenomesGenetics.jkab 2021;11(8):166.

122.

Gupta

, Tölzer

, Sari-Ak

, Fitzgerald

, Schaffitzel

, Berger

MultiBac: Baculovirus-Mediated Multigene DNA Cargo Delivery in Insect and Mammalian Cells, Viruses 2019;11(3):198.

123.

Hong

, Li

, Xue

, Zhang

, Cui

, Wang

,et al. Genetic engineering of baculovirus-insect cell system to improve protein production, Front Bioeng Biotechnol 2022;10:994743.

124.

Chang

, Liu

, Chen

, Hu

, Burov

, Puzyr

, et al. Study of the immunogenicity of the VP2 protein of canine parvovirus produced using an improved Baculovirus expression system, BMC Vet Res 2020;16:202.

125.

Tripathi

, Shrivastava

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development, Front Bioeng Biotechnol 2019;7:420.

126.

Wang

, Zhao

, Li

, Ma

, Kornberg

, Nie

Harnessing coronavirus spike proteins’ binding affinity to ACE2 receptor through a novel baculovirus surface display system, Biochem Biophys Res Commun 2022;606:23–8.

127.

Torres

TZB

, Prince

, Robison

, Rückert

Optimized In Vitro CRISPR/Cas9 Gene Editing Tool in the West Nile Virus Mosquito Vector, Culex quinquefasciatus, Insects 2022;13(9):856.

128.

Zhang

, Xiong

, Xie

, Shen

, Chen

, Ye

, et al. Optimization and Application of CRISPR/Cas9 Genome Editing in a Cosmopolitan Pest, Diamondback Moth, Int J Mol Sci 2022;23(21):13042.

129.

Aulicino

, Pelosse

, Toelzer

, Capin

, Ilegems

, Meysami

, et al. Highly efficient CRISPR-mediated large DNA docking and multiplexed prime editing using a single baculovirus, Nucleic Acids Res 2022;50(13):7783–99.